On Oct 10, major Wall Street analysts update their ratings for $Travere Therapeutic (TVTX.US)$, with price targets ranging from $20 to $41.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and maintains the target price at $20.
Evercore analyst Liisa Bayko maintains with a buy rating, and adjusts the target price from $12 to $30.
Guggenheim analyst Vamil Divan maintains with a buy rating, and adjusts the target price from $23 to $41.
Wedbush analyst Laura Chico maintains with a buy rating, and adjusts the target price from $17 to $25.
CCORF analyst Edward Nash maintains with a buy rating, and maintains the target price at $22.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Following a recent scientific workshop, there is growing excitement within the medical community about the potential of using proteinuria as a primary endpoint in clinical trials. Should this be embraced by regulatory bodies, it would have decidedly favorable consequences for treatments targeting conditions such as focal segmental glomerulosclerosis (FSGS). In light of these developments, expectations are being cautiously adjusted to include a projected market introduction for such therapies, with conservative estimates anticipating a launch year and the likelihood of successful outcomes.
Following the recent PARASOL Working Group meeting in Bethesda, MD, which brought together representatives from various sectors to deliberate on endpoints for focal segmental glomerulosclerosis trials, two primary insights emerged. Firstly, there is an incentive to transition away from eGFR as a trial endpoint in FSGS. Secondly, proteinuria is being considered as a potential validated surrogate endpoint within these trials. It is anticipated that Travere will seek a meeting with the FDA and aim to submit an sNDA in the first half of 2025. The final results from PARASOL are expected to be shared at the ASN meeting and in a scholarly publication. Additionally, should approval be granted, it could enhance Travere's attractiveness as a potential M&A target.
The completion of the PARASOL workshop has increased confidence in the potential approval of Filspari for the treatment of focal segmental glomerulosclerosis (FSGS), resulting in an enhanced probability of success estimate for Filspari in treating FSGS to 75% from the previous 60%.
Here are the latest investment ratings and price targets for $Travere Therapeutic (TVTX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
